SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Howard Hughes — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientHoward Hughes
Date of birth1905-12-24
IdentifiersMRN HR-ML006-SYN-TD; SSN (made up) 000-06-5571
Document date1947-10-05
AuthorAnselm Garrity-Moyo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twenty-two-week review: OCD response, buprenorphine, pain, weight and laboratory checks. [S]

History of Present Illness

Mr. Hughes returns three weeks after his preventive visit and twelve weeks after the increase to sertraline 200 mg, which he tolerates with mild night sweats; the nurse call two weeks after the increase found no problems. He has had twenty exposure sessions. He eats in a restaurant once a week, holds meetings without asking visitors about illness, and no longer needs sealed milk bottles. Washing and checking take about one hour a day, and he says the fears are now "background noise." He has used no opioid other than buprenorphine; the urine test today was positive for buprenorphine and negative for other opioids and fentanyl. He wears his hearing aids every day and uses the remote microphone in meetings. He would like his COVID-19 vaccine today. [S]

ElementDetail
RitualsAbout one hour a day; Y-BOCS 14
Sertraline200 mg for twelve weeks; mild night sweats
Buprenorphine8 mg twice daily; urine test as expected
PainPEG 4.0
Weight76.2 kg, up 4.2 kg since intake

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight up
GastrointestinalNegativeBowels regular
MusculoskeletalPositiveMild chest wall and back pain on long days
PsychiatricNegativeContamination fears mild; mood good; no thoughts of suicide or of harming anyone

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 300 mg with codeine 30 mg oral tablet, prescribed elsewhere since the crash as one or two tablets every 6 hours as needed, no more than 8 a day; he has been taking 10 to 12 a dayOne or two tablets every 6 hours as needed, no more than 8 a dayOral route1947-05-04 to 1947-05-11completedS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staffOne spray as needed for suspected overdose; repeat in 2 to 3 minutes if neededNasal route1947-05-04activeS
Buprenorphine 2 mg with naloxone 0.5 mg sublingual film for the first day: 4 mg once withdrawal is moderate (COWS 12 or more), then 2 to 4 mg every one to two hours as needed, to no more than 16 mg on the first dayFirst-day induction by the written plan, no more than 16 mgSublingual route1947-05-11 to 1947-05-12completedS
Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at firstOne film under the tongue twice dailySublingual route1947-05-12activeS
Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stoppedTwo tablets three times daily, no more than 3,000 mg a dayOral route1947-05-11activeS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1947-05-11 to 1947-06-08completedS
Sertraline 100 mg oral tablet, one tablet dailyOne tablet dailyOral route1947-06-08 to 1947-07-13completedS
Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCDTwo tablets dailyOral route1947-07-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1947-10-05Body height191cmS
1947-10-05Body weight76.2kgS
1947-10-05Body mass index (BMI) [Ratio]20.9kg/m2S
1947-10-05Systolic blood pressure118mm[Hg]S
1947-10-05Diastolic blood pressure76mm[Hg]S
1947-10-05Heart rate72/minS
1947-10-05Respiratory rate14/minS
1947-10-05Body temperature36.6CelS
1947-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1947-10-05Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1947-10-05Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1947-10-05Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.74-1.35 mg/dLNormalS
1947-10-05Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1942)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1947-10-05Glucose [Mass/volume] in Serum or Plasma86mg/dL70-99 mg/dLNormalS
1947-10-05Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-40 U/LNormalS
1947-10-05Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-56 U/LNormalS
1947-10-05Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
1947-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1947-10-05Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1947-10-05Mean score [PEG]4{score}S

Physical Exam

Vital signs recorded on 1947-10-05; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/76, pulse 72; weight 76.2 kg, BMI 20.9
SkinHands healed
MusculoskeletalFull left shoulder elevation; mild tenderness of the left lower ribs
PsychiatricRelaxed and humorous; insight good

Problems

ProblemClinical statusVerificationCodeProvenance
Intrusive fears of contamination by germs for about a year, worse since the crash, with hand washing, cleaning of objects and avoidance of handshakes, shared spaces and food handled by others, taking about four hours a day; he recognizes the fears are probably excessive; cause under evaluationresolvedconfirmed R46.81S — Synthetic presenting problem anchored to his documented fear of germs; resolved into the diagnosis of OCD at the consultation. Not a claim about his real symptoms in 1947.
Obsessive-compulsive disorder, contamination type, with good or fair insight, not tic-related; Y-BOCS 28 (severe) at intake; no post-traumatic stress disorder on screeningactiveconfirmed F42.2S — Synthetic modern diagnosis made at the consultation, linked to the retrospective interpretation of his documented fears (R). Not a claim about his real diagnosis.
Opioid use disorder, moderate (four of the DSM-5-TR criteria that count for a prescribed opioid: taking more than prescribed, failed attempts to cut down, time spent getting prescriptions from two prescribers, and craving), on codeine prescribed after a crash; buprenorphine plannedactiveconfirmed F11.20S — Synthetic modern coding; tolerance and withdrawal are not counted for a medicine taken under medical supervision. Person-first language; not a claim about his real diagnosis.
Chronic pain after major trauma ten months ago (crushed chest with rib fractures, collapsed lung, other fractures and burns): chest wall, left shoulder and low back pain, PEG 6.7activeconfirmed G89.21S — Synthetic modern diagnosis anchored to his documented injuries.
Difficulty hearing conversation, worse in noise, after years of flying in loud aircraft; cause under evaluationresolvedconfirmed H91.93S — Synthetic presenting problem; resolved into a diagnosis when audiometry was done at five weeks. His documented deafness is from later years.
Bilateral high-frequency sensorineural hearing loss with a notch at 4000 Hz, consistent with noise exposure from flying; hearing aids fittedactiveconfirmed H90.3S — Synthetic modern diagnosis made at five weeks; not a claim about his real hearing in 1947.
Weight loss of about 8 kg since the crash (BMI 19.7), from eating little outside food he has prepared or inspected himself because of contamination fearsactiveconfirmed R63.4S — Synthetic nutrition problem linked to the contamination fears; not a claim about his real weight in 1947.
Acute bronchitis, likely viral, for five days; no pneumonia on examination; resolved within three weeks without antibioticsresolvedconfirmed J20.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyOCD severity (Y-BOCS, clinician-rated) and time spent on ritualsEvery visitCompleted todayY-BOCS 14, a 50 percent fall; about one hour a day
ReferralExposure and response prevention: sessions attended and home practiceWeekly, then twice weeklyCompleted todayTwenty sessions attended; moving to weekly, then booster sessions
Medication safetySSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughtsEvery visit, and two weeks after each start or dose changeCompleted todayNurse call after the increase done; mild night sweats; sodium 140 mmol/L
Self-managementAccommodation by staff, reduced step by step with his consentEvery visitCompleted todayNo rituals carried out by staff apart from his own choice of sealed water bottles at the factory
SurveyDepression (PHQ-9) and anxiety (GAD-7)At baseline and at least monthly during acute treatmentCompleted todayPHQ-9 4, item 9 scored 0; GAD-7 6
SurveySuicide risk review, safety plan and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or of harming anyone; 988 in his phone
Self-managementOpioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation)Every visitCompleted todayNo cravings and no other opioid use
LaboratoryUrine drug test with fentanyl and buprenorphine, with consentAt start, then about monthly in the first monthsCompleted todayPositive for buprenorphine, negative for fentanyl and other opioids
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's buprenorphine
Medication safetyNaloxone at home and household staff trainedEvery visitCompleted todayNaloxone at home
SurveyPain intensity and interference (PEG) and functionEvery visitCompleted todayPEG 4.0
ExaminationWeight, meals and nutritionEvery visitCompleted today76.2 kg, BMI 20.9; albumin 4.2 g/dL
LaboratoryKidney function, liver enzymes and albuminAt baseline and at about six months on scheduled acetaminophenCompleted todayPotassium 4.3 mmol/L, creatinine 0.96 mg/dL, eGFR 102, glucose 86 mg/dL, AST 24, ALT 27
ImagingHearing: audiometry, hearing aids and useAudiometry once; hearing aid review after fittingCompleted todayAudiologist review last month; hearing aids worn daily

Goal progress:

Immunizations given today: COVID-19 vaccine for the coming season [S]

Guideline basis: Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007); Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013); Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Prescription Drug Monitoring Programs (PDMPs) (2026); Hearing loss in adults: assessment and management (NG98) (2018); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Adult Immunization Schedule by Age (2026)

Follow-up: COVID-19 vaccine given today. Second hepatitis B dose next week. Review in three months. Call the clinic or 988 at any time. [S]